|Mr. James Christopher Passin||Co-Founder, CEO & Director||8.08k||N/A||1972|
|Mr. Kenneth E. Kovan||Co-Founder, Pres & COO||16.3k||N/A||1963|
|Mr. Lachlan McLeod CPA||CFO & Corp. Sec.||12.12k||N/A||1988|
|Dr. David Berd||Co-Founder & Chief Medical Officer||N/A||N/A||1943|
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. It develops BVX-0320, a monovalent SARS-CoV-2 vaccine; and BVX-0918A, a haptenized tumor antigen vaccine for ovarian cancer, as well as and Covid-T, which screens for an immune system response in patients exposed to SARS-CoV-2. The company is also developing Papilocare for human papilloma virus (HPV)-dependent cervical lesions; BVX-0918C for cervical cancer; BVX-0204 HPV viral vaccine; and BVX-0121, a multivalent SARS-CoV-2 vaccine. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and Covid-T; research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320; and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its Covid-T immunodiagnostic. The company is headquartered in Vancouver, Canada.
BioVaxys Technology Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.